ePrints

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Lookup NU author(s): Professor Anthony MoormanORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2020 by The American Society of Hematology. Improved personalized adjustment of primary therapy to the perceived risk of relapse by using new prognostic markers for treatment stratification may be beneficial to patients with acute lymphoblastic leukemia (ALL). Here, we review the advances that have shed light on the role of IKZF1 aberration as prognostic factor in pediatric ALL and summarize emerging concepts in this field. Continued research on the interplay of disease biology with exposure and response to treatment will be key to further improve treatment strategies.

Publication metadata

Author(s): Stanulla M, Cave H, Moorman AV

Publication type: Article

Publication status: Published

Journal: Blood

Year: 2020

Volume: 135

Issue: 4

Pages: 252-260

Online publication date: 23/01/2020

Acceptance date: 21/11/2019

ISSN (print): 0006-4971

ISSN (electronic): 1528-0020

Publisher: American Society of Hematology

URL: https://doi.org/10.1182/blood.2019000813

DOI: 10.1182/blood.2019000813

PubMed id: 31821407

Altmetrics

Share